Study aim: Determining the effect of licorice root extract on clinical and laboratory symptoms of patients with Covid-19 Design: This study was designed as a double-blind randomized controlled clinical trial (RCT) with placebo. Settings and conduct: 120 samples are selected use blood sampling referred to the affiliated hospitals of Shahid Beheshti University of Medical Sciences. Participants/Inclusion and exclusion criteria: Inclusion criteria :Includes people with laboratory confirmation of Covid virus 19 Age over 15 years Exclusion criteria Patient request to leave the study for any reason Request the treating physician to exclude the patient from the study for any reason History of drug allergies Patients with hypertension Group of patients with underlying disease Intervention groups: Alcoholic extract of licorice root will be purchased from Shirin Daroo Company and will be received in sterile packages. Prior to purchase, the manufacturer will receive a Certificate of Sale and Good Manufacturing Practice. The sample will be sent to Zarband Pharmaceutical Company before the final order for glycyrrhizin content analysis and microbial testing, and the result of the analysis will be received. Alcoholic extract of licorice will be obtained from Shirin Daroo company along with COA product analysis sheet. Then a sample of it will be sent to Zardband Pharmaceutical Company for confirmation of the mentioned parameters and final approval according to the standards mentioned in international pharmacopoeias. The microcrystalline cellulose compound under the brand name AVICEL (particle diameter: less than 50 micrometers) will be purchased as a placebo from the pharmaceutical company (Exir, Iran). Main outcome variables: Interleukin-six (IL-6), interleukin-one beta (IL-1β), tumor necrosis factor-alpha (TNF-α), fibrinogen, d-dimer, ferritin, International Normalized Ratio (INR), reaction protein C(CRP)